Zogenix, Inc. (NASDAQ:ZGNX) tinted gains of +3.6% (+1.65 points) to US$47.45. The volume of 0.34 Million shares climbed down over an trading activity of 530.05 Million shares. EPS ratio determined by looking at last 12 month figures is -2.87. Over the same time span, the stock marked US$62.75 as its best level and the lowest price reached was US$33.43. The corporation has a market cap of US$1.96 Billion.
Zogenix, Inc. (NASDAQ:ZGNX)’s earnings per share has been growing at a 6.9 percent rate over the past 5 year when average revenue increase was noted as -26 percent. The return on equity ratio or ROE stands at -40.5 percent while most common profitability ratio return on investment (ROI) was -29.4 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 7 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.42. 5 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Vuzix Corporation (NASDAQ:VUZI) is worth US$112.6 Million and has recently risen 2.04% to US$4.01. The latest exchange of 0.18 Million shares is below its average trading activity of 235.63 Million shares. The day began at US$4.07 but the price moved to US$4.07 at one point during the trading and finally capitulating to a session high of US$4.07. The stock tapped a 52-week high of US$9.6 while the mean 12-month price target for the shares is US$10.25.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.11, and a price to sales ratio of 14.62. For the past 5 years, the company’s revenue has grown 11.4%, while the company’s earnings per share has grown 5.4%. With an institutional ownership near 28%, it carries an earnings per share ratio of -0.93.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.